FRIDAY, April 25, 2025 -- The U.S. Preventive Services Task Force (USPSTF) recommends counseling for women at increased risk for perinatal depression (PND). This recommendation forms the basis of a draft recommendation statement published online April 22.

2025年4月25日，星期五——美国预防服务工作组（USPSTF）建议为有较高围产期抑郁症（PND）风险的女性提供咨询。这一建议是4月22日在线发布的草案建议声明的基础。

Researchers from the USPSTF reviewed the benefits and harms of primary care-relevant interventions to prevent PND to update the 2019 USPSTF recommendations. Seventy-five trials were identified, with 30,842 participants. Regardless of inclusion criteria, most trials recruited women at increased risk for PND, as reflected in higher event rates in the control groups than current U.S.

美国预防服务工作组（USPSTF）的研究人员审查了初级保健相关干预措施对预防产后抑郁症（PND）的益处和危害，以更新2019年USPSTF的建议。共确定了75项试验，涉及30,842名参与者。无论纳入标准如何，大多数试验招募了产后抑郁症风险增加的女性，这反映在对照组的事件率高于当前美国的水平。

estimates for PND. The researchers found that counseling was the most widely studied intervention and demonstrated the most consistent benefit in depression incidence and changes in depression symptoms. There were 27 trials of behavioral counseling interventions (6,583 participants), most commonly based on cognitive behavioral therapy or interpersonal therapy; these trials demonstrated a 17 percent lower risk for depression at longest follow-up.

研究人员发现，咨询是研究最广泛的干预措施，在抑郁发病率和抑郁症状的变化方面表现出最一致的益处。共有27项行为咨询干预试验（6,583名参与者），最常见的是基于认知行为疗法或人际治疗的干预措施；这些试验表明，在最长的随访期内，抑郁风险降低了17%。

Twelve trials involving 11,415 participants demonstrated a 21 percent reduction in depression incidence with educational interventions, but there was no difference in the standardized mean difference in change in depression symptoms..

涉及11415名参与者的12项试验表明，教育干预使抑郁症发病率降低了21%，但在抑郁症状变化的标准化平均差异方面没有区别。

Based on these findings, the USPSTF recommends that clinicians provide or refer those at increased PND risk for counseling interventions during pregnancy and the postpartum period (B recommendation).

基于这些发现，USPSTF建议临床医生在怀孕期间和产后阶段为那些患PND风险增加的人提供或推荐咨询干预（B级推荐）。

The draft recommendation statement and evidence review have been posted for public comment. Comments can be submitted from April 22 through May 19, 2025.

草案建议声明和证据审查已发布以征求公众意见。评论可以在2025年4月22日至2025年5月19日期间提交。

Draft Evidence Review

草案证据审查

Draft Recommendation Statement

草案建议声明

Comment on Recommendation Statement

对建议声明的评论

Whatever your topic of interest,

无论你感兴趣的话题是什么，

subscribe to our newsletters

订阅我们的新闻通讯

to get the best of Drugs.com in your inbox.

获取 Drugs.com 的最新资讯到您的邮箱。